Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion type Assertion NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_head.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion description "[The concentration of thrombin-activatable fibrinolysis inhibitor was particularly higher in patients with small cell carcinoma compared to those with adenocarcinoma or squamous cell carcinoma, and in cancer patients that responded to chemotherapy compared to non-responders.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_provenance.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion evidence source_evidence_literature NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_provenance.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion SIO_000772 15224354 NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_provenance.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion wasDerivedFrom befree-2016 NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_provenance.
- NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_assertion wasGeneratedBy ECO_0000203 NP450250.RArfsnFMClagLL0Azhv0ql43BHerOQ55Weu53ZPlvoZ9w130_provenance.